FDA declines to review Moderna application for new flu vaccine
#Moderna #FDA #Flu vaccine #mRNA technology #Biologics License Application #Regulatory approval #Pharmaceuticals
📌 Key Takeaways
- The FDA has issued a refusal to file a review for Moderna's new mRNA-based seasonal flu vaccine application.
- This decision is unexpected as the agency had previously given the project a 'green light' for development.
- Moderna is requesting an immediate meeting with regulators to discuss the refusal and seek a path forward.
- Industry analysts suggest this move could set a new precedent for how all updated and future vaccines are reviewed in the U.S.
📖 Full Retelling
The U.S. Food and Drug Administration (FDA) formally declined to review Moderna’s biologics license application for its new messenger RNA-based influenza vaccine this week, citing procedural shifts despite having previously granted the project an accelerated pathway. The federal agency's refusal to evaluate the potentially more effective seasonal flu shot comes at a critical juncture as the biotechnology firm seeks to expand its portfolio beyond COVID-19 treatments. This regulatory hurdle marks a significant setback for the Massachusetts-based company, which had expected a smoother transition toward commercializing its latest preventative healthcare technology following earlier positive signals from government health officials.
🏷️ Themes
Healthcare Regulation, Biotechnology, Public Health
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
<p>Moderna requests meeting to discuss refusal as decision could have implications for all new and updated vaccines</p><p>US regulators will not review Moderna’s request to license a new, potentially more effective flu shot – even though the US Food and Drug Administration (FDA) previously gave the green light to the project – in a decision that could have implications for all new and updated vaccines in the US.</p><p>It’s the latest move by the <a href="https://
Read full article at source